ClinicalTrials.gov
public full text
Public Domain
Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia Patients
The aim of this Phase I study is to evaluate the immunogenicity along with safety and toxicity as well as first efficacy of a multi-peptide vaccine adjuvanted with the TLR1/2 ligand XS15 emulsified in Montanide ISA 51 VG (AML-VAC-XS15) in AML patients who have achieved CR or CRi with first line treatment.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab#912738
- Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors#1030970
- Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers#887342
- CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms#1032066
- Novel Peptide Vaccination for Patients With Advanced Renal Cell Carcinoma#878757
Record · ID 906041
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive